Clinical and immune effects of fecal microbiota transplantation in children with acute graft-versus-host disease

Oleg V. Goloshchapov 1, Evgeny A. Bakin 1, Oksana V. Stanevich 1, Ruslana V. Klementeva 1, Alexander A. Shcherbakov 1, Alexander N. Shvetsov 1, Olesya V. Paina 1, Polina V. Kozhokar 1, Margarita V. Gorchakova 1, Elena V. Babenko 1, Maria A. SuvoROVA 1, Sergey N. Bondarenko 1, Maxim A. Kucher 1, Alexander D. Kulagin 1, Ludmila S. Zubarovskaya 1, Ivan S. Moiseev 1
1 Pavlov University, St. Petersburg, Russia
2 Explana Research Laboratory, St. Petersburg, Russia

Summary

Over last years, an important role of altered gut microbiota and its potential correction was suggested for pediatric cancer and autoimmune disorders. The data from last decade highlight sufficient influence of the main classes of gut bacteria (Firmicutes and Bacteroides) upon development of immune response in oncological disorders and autoagressive conditions, as well as role of their imbalance and its correction using fecal microbiota transplantation (FMT) approach. Our previous studies have shown a pronounced clinical effect of FMT, mostly, in adult patients with severe acute graft-versus-host disease (GVHD). The aim of this article was to present our own experience of FMT in children with intestinal form of GVHD resistant to conventional treatment.

Materials and methods. A prospective single-center study included 7 patients aged from 3 to 10 years with severe intestinal GVHD developed after allogeneic hematopoietic stem cell transplantation. Clinical effects of FMT were evaluated by conventional scales during 120 days after the procedure. Time-dependent changes of fecal microbiota were assayed, mainly, by the multiplex polymerase chain reaction (PCR) test-system. Results. We present our own experience of FMT in 7 children with intestinal GVHD and antibiotic-resistant colitis.

Conclusion

Complete or partial response to the GVHD treatment was achieved in 6 cases (86%) by 120 days, in absence of serious adverse events following FMT. Since day +8 after TFM, increased amounts of B. fragilis gr., Faecalibacterium prausnitzii and E. coli were registered in fecal microbiota (p< 0.048, p< 0.001, and p<0.048, respectively), in absence of differences for Bifidobacterium spp and Lactobacillus spp.

Keywords

Hematopoietic stem cell transplantation, graft-versus-host disease, fecal microbiota transplantation, clinical efficiency.

Introduction

Our knowledge on gut microbiota significantly extends over last decades, due to improved cultivation of fastidious bacteria and DNA-based classification. As a result, big classes of anaerobic microbes were revealed, thus allowing renewing phylogenetic tree of gut microflora. Over 80% of gut bacterial species do not grow on available bacteriological media [1]. Therefore, molecular biology methods (PCR and DNA sequencing) proved to be the most effective methods, both in experimental and clinical studies [1, 2]. Sequencing of 16S rRNA gene became the standard approach to phylogenetic attribution of numerous bacterial types and families inhabiting gut microbiota [3]. Implementation of these techniques allowed us both to assess species composition of gut microbiota (GM), and to revise the role of some bacterial groups in pathogenesis of oncological, infectious and autoimmune diseases. At the present time, two main types of bacteria dominate in human intestines, i.e., *Firmicutes* and *Bacteroidetes* [4]. Their ratio and species composition are changing from the first days of life and depends on the mode of birth. Early predomination of *Bacteroidetes* over *Firmicutes* is observed in the children born by physiological way. Such altered ratio may influence gut immunity, cause metabolic syndrome, as well as affect maturation of nervous system and immune response [5-9].

Impact of intestinal microbiota upon carcinogenesis and clinical course of malignant diseases is studied to much lesser degree. E.g., well-known antitumor immune surveillance depends on proper maturation of CD4+ T cells as well as cytotoxic NK and NK-T cells [10, 11]. Gut microbiota is known to be a potent educating factor of adaptive immunity. Hence, it may modulate growth of malignant cells, both in children and adults.

It is known, however, that anticancer therapy of leukemias and solid tumors in children is often associated with severe and durable disruption of intestinal microbiota. These changes are caused by damage of intestinal wall, inhibition of local anti-infectious immunity, usage of systemic broad-spectrum antibiotics. Such negative background results into decrease of the bacterial species with favorable immunological effects, e.g., *Bacteroidetes*, *Ruminococcaceae*, *Prevotella*, *Blautia*, and expansion of *Enterococci*, *Staphylococci* and Gram-negative microbiota which may cause septic complications [12-14].

Recent studies of gut microbiota with deep sequencing technologies have shown that qualitative and quantitative composition of this bacterial community determine the balance between antitumor immune response and immune-mediated complications. This effect is implemented via immune system, lymphocyte subpopulations and cytokine profile. Cancer patients with severe bacterial complications are virtually lacking both anti- as well a proinflammatory populations. Worth of note, neither significant anaerobic group was is observed in oncological patients using sequencing of target bacterial DNAAs. Transplantation of fecal microbiota remains the only currently available technique aimed for correction of the required bacterial populations. Of course, FMT is primarily used for treatment of disorders that do not respond to conventional therapies, e.g., resistant pseudomembranous colitis, or intestinal graft-versus-host disease (GVHD) refractory to immunosuppressive treatment.

The aim of current work is to assess effects of gut microbiota transplantation upon the course of severe inflammatory disorder, immune system changes, and gut microbiota correction in cases of life-threatening conditions in pediatric patients.

Patients and methods

Clinical characteristics and procedures

Over a period of 2015 to 2020, seven children (4 females and 3 males, 3 to 10 years old) were subjected to FMT. These patients were initially treated for acute lymphoblastic leukemia (n=4), hereditary disorders (n=3), or myelodysplastic syndrome (n=1). The reduced-intensity conditioning regimen included fludarabine with busulfan (n=3), melphanal (n=3), or cyclophosphamide (Cy) (n=1). Hematopoietic stem cell transplantation (HSCT) was performed from haploidentical donors (n=5), or matched related donors (n=2). Posttransplant prophylaxis of acute GVHD was carried out with Cy in 5 patients, combined with tacrolimus (n=5), mycophenolate mofetil (n=3), antilymphocyte globulin was used in three cases. In one patient, GVHD prophylaxis was performed with TCR alpha/beta depletion, rituximab, tocilizumab and abatacept. Despite the preventive therapy, severe intestinal GVHD with intestinal bleeding has been developed in all the described patients. In 2 patients, acute/chronic GVHD (overlap syndrome) was documented. Median term from beginning of acute intestinal GVHD or overlap-syndrome to FMT was 56 (8 to 889) days. Severity grade of acute GVHD was scored as grade IV in 4 cases, grade 3 in 2 children, and grade II, in one patient. In all the cases, treatment of acute intestinal GVHD was started with steroids at the dose of 2 mg/kg/day. In cases of failure, the therapy was escalat-ed with ruxolitinib (0.3 mg/kg/day), within clinical testing program performed by Russian Ministry of Healthcare (No.2016-29-1). Etanercept was added in 3 patients later in cases of poor effect (25 mg twice a week). Other therapies were applied, i.e., extracorporeal photopheresis (n=3), injections of mesenchymal stem cells (n=2), sirolimus (n=1) or tacrolimus (n=1).

General state of the patients at FMT was as follows: satisfactory in one case; moderate severity, in 2 patients; and four children were in severe condition. Clinical severity was determined, mainly, by assessment of pain and dyspeptic syndrome pronounced in all the patients. Intestinal bleeding with severe anemia was diagnosed in four patients, bilirubinemia, in 3 cases, pronounced encephalopathy was revealed in 2 children. Due to absence of sufficient clinical effect, FMT was administered, as adopted by the Pavlov University Ethical Board of 30.01.2017, №192). Both examination and treatment was performed under the conditions of Helsinki Declaration. The parents or caretakers signed appropriate informed consent. Inclusion criteria were as follows: acute GVHD grade II-IV, or overlap syndrome with intestinal disorder, steroid-refractory form of GVHD and...
failure of preceding treatment with etanercept or ruxolitinib. Exclusion criteria were not applied, due to severity of the disorder. All the children were in remission of primary disease.

Evaluation of acute intestinal GVHD severity, clinical response in the patients, characteristics of stool, undesirable adverse effects (AE) and pain syndrome was performed according to standard scales [15-19]. Histological examination of colon biopsies was carried out to confirm the intestinal GVHD diagnosis.

The FMT procedure in 5 patients was performed at the intensive care unit. In two cases, FMT was made in the outpatient setting. In four patients (57%), FT from third-party donors was used, and relatives served as donors in 3 cases (mother, in 1 case, and father, in 2 patients). In all these cases, the FT donors were also donors of hematopoietic stem cells for the same patient. Median age of the donors was 33 (19 to 38) years (4 females and 3 males). All the donors kept Mediterranean diet.

The routes of fecal transplant administration were as follows: EGD, 2 patients; EGD+ nasointestinal tube, 2 patients. Three children received fecal transplant (FT) per os, in gelatin capsules with frozen fecal microbiota. This route of administration was used for FMT in the patients and control persons [20]. Minimal age of the child treated with capsules was 4 years old.

Upon endoscopic FT administration, fresh native substance was used in two patients, and frozen native material was applied in other 2 cases. The frozen material was stored for a median time of 25 (2-104) days at -80°C. FT was delivered to upper intestine by means of nasointestinal tube, in 3.25 (2-5) séances; to lower intestine, using colonoscopy, 3 times. The gelatin capsules with frozen FT were administered daily 8 (5 to 10) times, at a dose of 3 to 6 capsules. Single FT dose applied via gastroscopy/nasointestinal tube was 1.7 (0.8-4.8) ml/kg; by colonoscopy, 9 and 6 ml/kg. Total dose of FT administered by the encapsulation method was 1.1 (0.6-1.7) g/kg.

Antibacterial prophylaxis was cancelled before FMT period in 3 patients; in one case, the therapy was resumed. Four other patients continued therapy with antibiotics. Due to proven viral gut affection (HHV 6 or EBV virus), four patients received gancyclovir therapy at a dose of 10 mg/kg daily.

Six patients recovered from GVHD and were followed after FMT at long terms (320-1964 days). Only one patient of the seven died on day +34 with pan-resistant *Klebsiella* sepsis.

**Special laboratory tests**

All the patients underwent clinical and laboratory examinations at the following terms: before FMT, on days +3, +16, +30, +60, and +120 after the procedure. The last day of FTM was considered Day 0.

Study protocols for FT donors, preparation of frozen encapsulated microbiota, native and frozen material, procedures for injection by intestinal catheters, storage and transportation of capsules with FT were described elsewhere in details [21].

Time dynamics of fecal microbiota before and after FMT was assessed by gene-specific PCR detection of DNA samples extracted from fecal samples using commercial Colonolnor test kit (Explana, St. Petersburg, Russia). This test system allowed quantitative detection of common gut bacteria, as based on multiplex real-time PCR (up to 20 specific bacterial genes and total molecular mass are targeted), being recalculated for CFU numbers as proposed by the manufacturer.

Immunophenotyping of lymphocyte subpopulations was performed by flow cytometry (Cytomix FC500, Beckman Coulter, USA), with CXP Analysis software (Beckman Coulter) using fluorochrome-labeled antibodies (CD45 FITC/CD4 PE/CD8 ECD/CD3 PC5, CD19PC7, CD3 FITC/CD(16+56) PE, CD45 PC5, CD5 FITC/CD23 PE/CD19 ECD, CD27 PC7, Beckman Coulter, USA), Versalyse protocol (Beckman Coulter, USA).

The patients were observed for a median of 585 (34-1948) days after FMT. Clinical response was evaluated according to common scales, assessing intestinal GVHD severity, and Bristol scale of stool quality.

**Statistical evaluation**

Due to small sample size, only methods of descriptive non-parametric statistics were used with Statistica software, to evaluate levels of significance for the differences between pre- and post-FMT indices.

**Results**

**Clinical effects of FMT using clinical response scales**

According to the results of clinical assessment by the mentioned scales, complete or partial response (resp., CR and PR) to the intestinal GVHD therapy was achieved in 6 patients out of 7 by the D+120 post-FMT, with a median time for CR and PR, of, respectively, 9 (2-45) and 34 (4-50) days.

Upon evaluation of the patients’ stool by the Bristol scale, partial response (>4 points) was achieved in 6 patients (86%) after 120 days, complete response (<4 points) was registered in 5 cases (71%). Median time for PR and CR following FMT comprised 23 (8-45) and 50 (10-90) days, respectively.

The patients reported positive dynamics after FMT, i.e., reduction of gut-related GVHD symptoms (stool volume, blood admixtures, abdominal pain), mitigated dyspeptic syndrome (vomiting, nausea, anorexia), as shown in Table 1.

**Composition and changes of fecal microbiota in FMT donors and recipients**

According to the results obtained by multiplex PCR (Colonolnor system), total intestinal bacterial mass (TBM) in the FT donors was as follows: 3×10^{12} (9×10^{11}-8×10^{12}) CFU/g, *Lactobacillus spp.*, 3×10^6 (1×10^5-2×10^6) CFU/g; *Bifidobacterium spp.*, 2×10^9 (9×10^7-3×10^9) CFU/g; *E.coli*, 3×10^4 (1×10^3-3×10^5) CFU/g; *B.fragilis group*, 2×10^{12} (2×10^{10}-5×10^{12}) CFU/g; *E.frausa.nzii*, 1×10^{10} (4×10^8-2×10^11) CFU/g.
Table 1. Time course of intestinal symptoms at different terms after fecal microbiota transplantation in children with acute GVHD (7 cases)

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>Terms, days after FMT</th>
<th>Before FMT</th>
<th>D+3</th>
<th>D+8</th>
<th>D+16</th>
<th>D+30</th>
<th>D+60</th>
<th>D+120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stool volume, ml/kg/d</td>
<td></td>
<td>37.7 (23.9-87.9)</td>
<td>34.9 (19.2-113.5)</td>
<td>28 (5-95.6)</td>
<td>20.2 (2.4-92.8)</td>
<td>17.1 (2.8-53.1)</td>
<td>5.7 (2-8.1)</td>
<td>4.4 (2-5.7)</td>
</tr>
<tr>
<td>Stool frequency/d</td>
<td></td>
<td>10 (4.6-19)</td>
<td>10.6 (2.7-22.0)</td>
<td>6 (2.2-21)</td>
<td>9 (2.4-21)</td>
<td>5 (3-15.4)</td>
<td>2.5 (2-4)</td>
<td>2 (1-3)</td>
</tr>
<tr>
<td>Stool consistency (Bristol scale)</td>
<td></td>
<td>6 (5-7)</td>
<td>6 (5-7)</td>
<td>5 (5-7)</td>
<td>5 (4-6)</td>
<td>5 (4-6)</td>
<td>4 (4-5)</td>
<td>4 (4-5)</td>
</tr>
<tr>
<td>Intestinal bleeding (CTCAE score, 1 to 5)</td>
<td></td>
<td>3 (0-4)</td>
<td>1 (0-4)</td>
<td>0 (0-2)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
</tr>
<tr>
<td>Vomiting frequency/d</td>
<td></td>
<td>3 (0-10)</td>
<td>0.1 (0-5)</td>
<td>0 (0-6)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
</tr>
<tr>
<td>Nausea (CTCAE score, 1 to 3)</td>
<td></td>
<td>2 (1-3)</td>
<td>2 (1-3)</td>
<td>1 (1-3)</td>
<td>1 (0-3)</td>
<td>1 (0-1)</td>
<td>1 (0-1)</td>
<td>1 (0-1)</td>
</tr>
<tr>
<td>Anorexia (CTCAE 1 to 5)</td>
<td></td>
<td>4 (2-4)</td>
<td>3 (1-4)</td>
<td>3 (1-4)</td>
<td>3 (1-4)</td>
<td>3 (0-4)</td>
<td>1 (0-2)</td>
<td>1 (0-2)</td>
</tr>
<tr>
<td>Abdominal pains (vis.-analogue scale)</td>
<td></td>
<td>7 (0-10)</td>
<td>8 (0-10)</td>
<td>1 (0-10)</td>
<td>3 (0-10)</td>
<td>0 (0-10)</td>
<td>0 (0-10)</td>
<td>0 (0-10)</td>
</tr>
</tbody>
</table>

Note: The data are presented as median values, with minimal and maximal scores in parentheses.

In the patients, when comparing median values for microbial contents post-FMT, some sufficient dynamics was revealed against initial values (Fig.1). E.g., a significant increase of total bacterial mass was registered on D+120 (p<0.02). Since D+3, increased values against initial levels were found for *B.fragilis* group, *F.prausnitzii* and *E.coli* (respectively, p<0.048, p<0.001 and p<0.048), as seen from Fig. 1.

Figure 1. Time-dependent changes of the gut microbiota in pediatric patients (n=7) before and at different terms after fecal microbiota transplantation. Colored bars show median amounts of specific bacterial species and total bacterial mass (TBM).

Abscissa, days posttransplant. Ordinate, log10 of CFU numbers.

*E.coli* strains found in donor microbiota were tested by Colonolflor system (multiple PCR panel) and no enteropathogenic *E.coli* genes were revealed.

By the day +120, no significant differences were noted for *Bifidobacterium spp* and *Lactobacillus spp*, compared with their initial levels.

Individual changes of gut bacteria amounts are shown in Fig. 2. In cases of early death (n=1) and of the malignancy relapse (n=1), a decrease of *B.fragilis* and, to lesser degree, *Faecalibacterium prausnitzii* was noted by the end of observation periods (resp., on D+15 and D+120). Hence, recovery of *B.fragilis* may be an informative marker of gut microbiota recovery which should be tested in more representative groups of patients.

Immunological effects of FMT

Upon increase in major commensal microorganisms (*Bacteroides fragilis, Faecalibacterium prausnitzii*) shown by multiple PCR following FMT in patients with acute intestinal GVHD, the number of major lymphocyte subpopulations among surviving children was stable, or became substantially increased for NK cells (p<0.05), as seen from Table 2. On the contrary, in a patient with relapse of primary malignancy, and in the patient who died due to subsequent sepsis, the absolute numbers of major lymphocyte subpopulations were either decreased, or remained at subnormal levels with time, compared to the surviving patients (data not shown).

Adverse effects of FMT

In 6 patients (86%), we have observed undesirable events, probably connected with FMT procedure. All these symptoms manifested within 7 days after FMT. However, these side effects were not referred to serious events. Nausea, abdominal pains and stomach rumbling were the most common events (43%) followed by subfebrile rise of body temperature (29%). In a single case, vomiting, pronounced abdominal flatulence and intestinal paresis were documented. One patient died on D+34 after FMT with *K.pneumonia* sepsis diagnosed on D+5, accomplished by fast progression of intestinal GVHD. The patient was previously colonized with pan-resistant *K.pneumoniae* strain, thus excluding potential negative consequence of FMT procedure.
Figure 2. Time-dependent changes of the gut microbiota species and total bacterial mass in pediatric patients before and after fecal microbiota transplantation (FMT). Time dynamics of dead, recovered and recurred (relapsed) patients is marked, respectively, in red, green and blue.

Abscissa, terms after FMT, days. Ordinate, bacterial amounts per g of stool derived from multiplex PCR results, recalculated for CFU contents per sample.

Table 2. Time-dependent changes of main lymphocyte populations in peripheral blood of five patients with acute GVHD following fecal microbiota transplantation

<table>
<thead>
<tr>
<th>Population markers</th>
<th>Relative values</th>
<th>Before FMT</th>
<th>D+3</th>
<th>D+8</th>
<th>D+16</th>
<th>D+30</th>
<th>D+60</th>
<th>D+120</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD23+ (activated B cells)</td>
<td>median</td>
<td>6e-04</td>
<td>0</td>
<td>9e-04</td>
<td>0.0016</td>
<td>0.0012</td>
<td>0.044</td>
<td>0.0666</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.001</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>0.2009</td>
<td>0.2442</td>
<td>0.2788</td>
<td>0.252</td>
<td>0.2014</td>
<td>0.2622</td>
<td>0.1456</td>
</tr>
<tr>
<td>CD3-CD16+ (Natural killer cells)</td>
<td>median</td>
<td>0.0264</td>
<td>0.1815</td>
<td>0.1476</td>
<td>0.1624</td>
<td>0.1596</td>
<td>0.1715</td>
<td>0.1881</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0.0205</td>
<td>0.092</td>
<td>0.194</td>
<td>0.1204</td>
<td>0.1446</td>
<td>0.119</td>
<td>0.1518</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>0.0562</td>
<td>0.1947</td>
<td>0.2763</td>
<td>0.2925</td>
<td>0.165</td>
<td>0.1976</td>
<td>0.6552</td>
</tr>
<tr>
<td>CD3-CD19+ (B lymphocytes)</td>
<td>median</td>
<td>9e-04</td>
<td>0.0016</td>
<td>0.0099</td>
<td>0.0096</td>
<td>0.0012</td>
<td>0.111</td>
<td>0.3894</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>0.5617</td>
<td>0.4026</td>
<td>0.6396</td>
<td>0.6165</td>
<td>0.627</td>
<td>0.494</td>
<td>0.7696</td>
</tr>
<tr>
<td>CD3-CD16+ (T killer cells)</td>
<td>median</td>
<td>0.0048</td>
<td>0.0099</td>
<td>0.0205</td>
<td>0.027</td>
<td>0.0153</td>
<td>0.017</td>
<td>0.0264</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0.0027</td>
<td>0</td>
<td>0.0148</td>
<td>0.0074</td>
<td>0.0152</td>
<td>0.0076</td>
<td>0.0198</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>0.041</td>
<td>0.0099</td>
<td>0.0459</td>
<td>0.0384</td>
<td>0.027</td>
<td>0.033</td>
<td>0.0884</td>
</tr>
<tr>
<td>CD3-CD19- (Total T cells)</td>
<td>median</td>
<td>0.2676</td>
<td>0.0951</td>
<td>0.6093</td>
<td>0.5728</td>
<td>0.4134</td>
<td>0.599</td>
<td>2.6367</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0.0389</td>
<td>0.0702</td>
<td>0.0772</td>
<td>0.0808</td>
<td>0.1312</td>
<td>0.195</td>
<td>0.2442</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>3.4235</td>
<td>2.6103</td>
<td>3.239</td>
<td>3.483</td>
<td>2.8614</td>
<td>2.9374</td>
<td>3.5568</td>
</tr>
<tr>
<td>CD3+CD4+ (Helper T cells)</td>
<td>median</td>
<td>0.111</td>
<td>0.0537</td>
<td>0.306</td>
<td>0.236</td>
<td>0.1758</td>
<td>0.433</td>
<td>1.378</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0.0218</td>
<td>0.0376</td>
<td>0.0388</td>
<td>0.044</td>
<td>0.0957</td>
<td>0.1525</td>
<td>0.138</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>2.3821</td>
<td>1.8843</td>
<td>2.419</td>
<td>2.511</td>
<td>1.9608</td>
<td>2.0634</td>
<td>1.8084</td>
</tr>
<tr>
<td>CD3+CD8+ (Cytotoxic T cells)</td>
<td>median</td>
<td>0.1497</td>
<td>0.0399</td>
<td>0.2421</td>
<td>0.2848</td>
<td>0.198</td>
<td>0.192</td>
<td>0.693</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>0.0031</td>
<td>0.0306</td>
<td>0.0476</td>
<td>0.0488</td>
<td>0.0081</td>
<td>0.009</td>
<td>0.0654</td>
</tr>
<tr>
<td></td>
<td>max</td>
<td>0.9594</td>
<td>0.6435</td>
<td>0.7175</td>
<td>0.855</td>
<td>0.6992</td>
<td>0.6574</td>
<td>2.0384</td>
</tr>
</tbody>
</table>

Note: increased ratio of NK cells is shown in bold.
Discussion

FMT is presently introduced as experimental therapeutic option for treatment of clinical syndromes with pronounced gut dysbiosis. E.g., incidence of C. difficile infection (CDI) in children and adults is sufficiently increased since 2000 [22-24]. Recurrent CDI develop in ca. 15-30% of pediatric patients with this infection [25, 26]. C. difficile-associated syndrome may cause different clinical pattern: from gut colonization to severe fulminant colitis. Many effective antibiotics and immunological therapies are adopted for C. difficile management in adults. However, therapeutic options for children are currently limited [27]. A recent large multicenter study of more than 300 patients aged from 11 to 23 years with C. difficile-associated infection has shown that FMT was clinically successful in 81% and 90% of the cases after 1st and 2nd FMT, respectively [28]. FMT becomes a part of therapeutic protocols in pediatrics, when treating recurrent C. difficile infection, being introduced into appropriate guidelines for pediatric patients [29].

There are also some studies of FMT in children with ulcerative colitis [30]. FMT was performed in 21 patients at a mean age of 12 years, in whom clinical response was observed in 57% and 28%, respectively, at 1 and 6 months after the procedure [31].

Of interest, the prospective study of FMT effects in 20 patients colonized with multiple drug-resistant (MDR) bacteria. Full decolonization of MDR microorganisms was registered in 15 patients [32]. In other study, decolonization of carbapenemase-producing and vancomycin-resistant bacteria was achieved following FMT in 7 of 10 patients [33]. To our knowledge, usage of FMT for decolonization of pan-resistant Gram-negative microbes was not yet reported in pediatric practice. However, FMT in childhood is used rather rarely, due to potential hazards and non-validated treatment techniques. First pediatric FMT was performed 10 years ago in a child 2 years old with recurrent Clostridium difficile infection resistant to standard therapy [34].

Acute GVHD after HSCT, with mortality rates up to 90%, is another complication treated by FMT [35]. Gut dysbiosis in children with acute GVHD was recently demonstrated, with sufficient decrease in anaerobic Firmicutes associated with “anti-inflammatory” effects (Clostridiales, Erysipelotrichaceae, Eubacteriaceae, Lachnospiraceae and Ruminococcaceae), compared to GVHD-free patients [36].

Interestingly, the children free of intestinal GVHD exhibited high intestinal levels of obligate anaerobes (Ruminococcaceae) accompanied by fast NK- and B cell reconstitution, and decreased mortality. Vice versa, severe GVHD was related to higher contents of Lactobacillaceae in gut microbiota [37].

The ratio of Enterococcus in adult patients without acute intestinal GVHD was 21% compared to 46% incidence in those who subsequently developed this complication, being increased to 74% in presence of active intestinal GVHD [38]. Meanwhile, Enterococcus spp. was shown to affect epithelial barrier and promote TNF production by the macrophages [39].

Potential efficiency of FMT in acute intestinal GVHD was initially shown in [40]. Complete remission of steroid-resistant intestinal GVHD was reported in 3 of 4 patients following FMT, thus considering this option a quite promising approach for this indication. Current data on FMT usage in acute intestinal GVHD in pediatric patients are quite limited [41].

While being an experimental therapeutic option, pediatric FMT may be applied only at large medical centers, due to lacking treatment standards and absence of appropriate clinical and laboratory staff. However, distinct clinical situations may require urgent FMT intervention, e.g., recurrent fulminant colitis associated with C. difficile infection, or acute severe intestinal GVHD refractory to any immunosuppressive therapy, thus presuming optional off-label FMT procedure. To perform the off-label FMT treatment, this approach meets the following criteria: (1) Severe disorder which is life-threatening, or causing a long-term impaired quality of life; (2) Absence of specific treatment methods; (3) Analysis of research data allows to suggest that the given preparation may achieve clinical effect in the given patients. Moreover, FDA (USA) interprets FMT usage in the following way: if the state of patient without any treatment may move from less severe to more serious, and if a potentially better therapy is available, compared to existing treatment methods. Indications for FMT procedure in acute intestinal GVHD seem to be consistent with these requirements [42].

Safety issues are of most importance in pediatrics, especially, for immunocompromised children following allogeneic HSCT. A sufficient retrospective safety study was performed in 49 children who received 114 FMT procedures [43]. Incidence of short-term undesirable events (UDE) within 48 hours was 26% (30/114). Two severe UDE were observed, and one patient was lost due to bloodstream infection and hepatic failure at 4th week following FMT, with total mortality of 2.04%. Notably, immune state was an independent factor which sufficiently influenced clinical outcomes (p=0.002). Risk quotient in the patients with immune deficiency proved to be 3.1. Hence, we must be cautious when performing FMT in children with immune deficiencies.

In the present study, we observed potentially FMT-related adverse effects in 86% of the cases. However, the undesirable events were not classified as serious, requiring only symptomatic therapy. Longitudinal changes in gut microbiota, metabolome and immune system were not assessed. The observation terms after our 1st pediatric FMT exceed 5 years, without detectable anomalies in growth and developmental, or behavioral deviations. One should observe other patients from our FMT series to these purposes.

To perform FMT in children with intestinal GVHD, encapsulated form of frozen microbiota was used. The youngest patient who received capsules with fecal microbiota was 4 years old. Some FMT studies with capsule administration suggest lower age limits (over 7 years old) for the patients with C. difficile-associated infection [44]. We guess, however, that the main factor is the patient’s ability to take encapsulated preparation, not age. According to a survey among 58 gastroenterologists, administration of oral capsules with microbiota to the patients was preferred by 34% of clinicians [45].
Usage of encapsulated form in FMT allows to avoid more invasive procedures, thus being more safe for the children, decreasing both complication rates and treatment costs. In our study, we, generally, followed the FMT protocol proposed by Shouval et al. [46].

There are still insufficient data for a full objective assessment of FMT efficiency in pediatric patients with acute intestinal GVHD, e.g., due to lack of appropriate comparison group. However, our results provide evidence of complete clinical response in 6 of 7 cases within 34 (4 to 50) days after FMT. We guess that, in intestinal GVHD, clinical evaluation by means of validated Bristol scale is quite indicative to assess stool normalization and recovery of intestinal functions. By these criteria, complete response (<4 points, solid faeces) was achieved in 5 children (70%) with steroid-resistant gut GVHD within 10-90 days (median of 50 days), thus being an impressive result. In our previous study which included a mixed-age group treated by FMT (13 adults and 6 children), and 8 control cases (4 adults and 4 children), we have obtained similar results, i.e., a distinct trend for a faster clinical response was observed in FMT group [47]. The median terms for development of complete response were 34 (3–90) versus 75 (6–91) days in controls. Complete clinical response (CCR) in the FMT group was documented in majority of cases by the day +60. Clinical improvement in the patients with intestinal GVHD was accompanied by restoration of intestinal B.fragilis, E.prausnitzii and E.coli contents. In contrast, placebo-treated patients did not exhibit any CCR by the day +30, and only one patient achieved complete response by the day +60.

Immunotropic effects of commensal gut bacteria, especially, upon major lymphocyte subpopulations may be of great importance for successful therapy of acute intestinal GVHD and survival of children following HSCT. Different lymphocyte dynamics in surviving and deceased patients is in accordance with current views that microbiota may influence human immunity. In our previous study, distinct changes in immune state were shown after FMT in healthy volunteers [20]. An increase in absolute and relative counts of T-helper cells (CD3+ CD4+ CD19+ CD23+) was found by +9, along with decline in the numbers of cytotoxic T cells (CD3+ CD8+) and NK-cells (CD3-CD16+ 56+). A reversal to normal values was revealed by the D+30.

Other indications for FMT in hematology malignancy are widely discussed recently. Most effects of FMT are yet poorly explored. However, one may formulate several clinical applications for FMT: decolonization of the microorganisms with multiple drug resistance; treatment of C.difficile-associated infection; therapy of autoimmune colitis developing after treatment with PD-1 inhibitors (Nivolumab), or anti-CD20 antibodies (Rituximab) therapy; gut dysbiosis following massive antibacterial therapy; changing sensitivity of malignancies for targeted drugs.

Ethical aspects should be definitely observed, i.e., FMT perception by the children with acute GVHD and their patients. When treating pediatric patients with ulcerative colitis, the authors report tolerance for FMT, and readiness for continuing the therapy [48]. In our opinion, education of parents about the main purposes, mechanisms of FMT action, and its safety should be of utmost importance.

Conclusion

FMT might be effective in children with severe intestinal GVHD following HSCT. FMT is a relatively safe and feasible procedure in immunocompromised patients upon careful screening of the third-party donors. However, our study has some limitations, i.e., small number of the group and absence of randomized controls. Therefore, larger prospective studies should be performed to better assess safety of FMT in pediatric patients with severe GVHD. Moreover, additional longitudinal studies are required, especially in pediatric patients, in order to assess potential changes in microbiota, metabolome, and immune system. Effective usage of FMT is a pre-requisite for implementation of novel anaerobic bacterial preparations which seem to be used in future, not only for treatment of antibiotic-resistant infections, but also to prevent tumor progression and autoimmune diseases. High-throughput DNA sequencing may provide additional evidence for application of microbiota-based biotherapy in pediatrics.

Acknowledgement

The study was partially supported by the AdVita Charity Foundation.

Conflicts of interest

None reported.

References


Клинико-иммунологические эффекты трансплантации фекальной микробиоты у детей с острой реакцией трансплантат против хозяина

Олег В. Голощапов 1, Евгений А. Бакин 1, Оксана В. Станевич 1, Руслана В. Клементьева 1, Александр А. Щербаков 1, Александр Н. Швецов 1, Олеся В. Панина 1, Полина В. Кожокарь 1, Маргарита В. Горчакова 1, Елена В. Бабенко 1, Мария А. Суворова 2, Сергей Н. Бондаренко 1, Максим А. Кучер 1, Александр Д. Кулагин 1, Людмила С. Зубаровская 1, Иван С. Моисеев 1

1 Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
2 ООО «Эксплана», Санкт-Петербург, Россия

Резюме

На протяжении последних лет установлена важная роль нарушений кишечной микробиоты и ее потенциальной коррекции при злокачественных новообразованиях и аутоиммунных заболеваниях у детей. Данные последнего десятилетия выявили существенное влияние основных классов кишечных бактерий (Firmicutes и Bacteroides) на развитие иммунного ответа при онкологических заболеваниях и аутоагрессивных состояниях, а также роль их дисбальанса и коррекции посредством трансплантации фекальной микробиоты (ТФМ). Наши предыдущие исследования показали выраженный клинический эффект ТФМ, в основном, у взрослых пациентов с тяжелой острой реакцией «трансплантат против хозяина» (РТПХ). Целью настоящей работы было представить наш опыт ТФМ у детей с кишечной формой острой РТПХ, резистентной к обычному лечению.

Материалы и методы

Проспективное одноцентровое исследование включило 7 пациентов в возрасте от 3 до 10 лет с тяжелой кишечной РТПХ после аллогенной трансплантации гемопоэтических стволовых клеток. Клинические эффекты ТФМ определяли с применением стандартных шкал на протяжении 120 сут. после данной процедуры. Временную динамику состава фекальной микробиоты оценивали, главным образом, посредством мультиплексной ПЦР тест-системы.

Результаты

Мы представили собственный опыт ТФМ у 7 детей с кишечной формой острой РТПХ и антибиотико-резистентным колитом. Полный или частичный ответ на этот вид лечения РТПХ был достигнут в 6 случаях (86%) в течение 120 сут. в отсутствии серьезных нежелательных эффектов после ТФМ. С 8-го дня после ТФМ было отмечено нарастание содержания B. fragilis gr., Faecalibacterium prausnitzii и E. coli в фекальной микробиоте (р< 0,048, р< 0,001, и р<0,048, соответственно), при отсутствии различий по Bifidobacterium spp. и Lactobacillus spp.

Выводы

Комбинированная терапия иммуносупрессивными препаратами и ФМТ у пациентов с кишечной формой РТПХ, резистентной к стандартной терапии, сопровождается выраженным клиническим ответом, коррелирующим с определенными изменениями кишечной микробиоты и приемлемыми показателями безопасности процедуры.

Ключевые слова

Трансплантации фекальной микробиоты, трансплантация гемопоэтических клеток, реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, клиническая эффективность, побочные эффекты.